stoxline Quote Chart Rank Option Currency Glossary
  
Eloxx Pharmaceuticals, Inc. (ELOX)
0.0001  0 (0%)    02-05 15:00
Open: 0.0001
High: 0.0001
Volume: 1,745
  
Pre. Close: 0.0001
Low: 0.0001
Market Cap: 0(M)
Technical analysis
2025-02-06 11:18:31 AM
Short term     
Mid term     
Targets 6-month :  0 1-year :  0
Resists First :  0 Second :  0
Pivot price 0
Supports First :  0 Second :  0
MAs MA(5) :  0 MA(20) :  0
MA(100) :  0 MA(250) :  0.47
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  0 D(3) :  1
RSI RSI(14): 3.7
52-week High :  1.38 Low :  0
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ELOX ] has closed above bottom band by 50.0%. Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0 - 0 0 - 0
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0
Company Description

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Headline News

Tue, 12 Nov 2024
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments - GlobeNewswire

Thu, 17 Oct 2024
Eloxx Pharmaceuticals enacts option repricing for CEO - Investing.com

Thu, 11 Jul 2024
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates - GlobeNewswire

Tue, 16 Apr 2024
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates - GlobeNewswire

Tue, 16 May 2023
Why Is Eloxx Pharmaceuticals (ELOX) Stock Down 27% Today? - InvestorPlace

Wed, 30 Mar 2022
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 3 (M)
Shares Float 3 (M)
Held by Insiders 0.4 (%)
Held by Institutions 19.5 (%)
Shares Short 21 (K)
Shares Short P.Month 34 (K)
Stock Financials
EPS -8.89
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -6.54
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -73.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -6.13
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -8 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.01
Price to Sales 0
Price to Cash Flow -0.01
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android